Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 3020 (LINC03020) is a member of the long intergenic non-coding RNA (lincRNA) family, a subgroup of long non-coding RNAs (lncRNAs) that are longer than 200 nucleotides and do not overlap with annotated protein-coding genes[3][5]. LincRNAs are known to perform diverse regulatory functions in the cell, including chromatin remodeling, regulation of transcription, acting as molecular scaffolds, decoys, or sponges for proteins and microRNAs, and fine-tuning gene expression in a tissue-specific manner[1][5]. However, there are currently no published studies that detail the specific biological roles, disease associations, or therapeutic potential of LINC03020 itself. LINC03020 has gene entries in major databases, such as NCBI Gene (101926892) and Ensembl (ENSG00000253967), confirming its annotation as a non-protein-coding transcript[3]. It is not recognized as a therapeutic target or a known biomarker, and no drugs or safety concerns are associated with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 3020 (LINC03020).